Market entry opportunities As a commercial-stage biopharma focused on ophthalmic diseases with a FDA approved nasal spray Tyrvaya for dry eye, Oyster Point Pharma presents partnership and distribution opportunities with large specialty retailers, ophthalmology clinics, and payers to expand formulary access and geographic reach.

Expansion potential With a small employee base (11-50) and recent leadership moves including promotion within compliance and ethics, there may be accelerators for selling and channel development through strategic licensing, alliances, or co-promotion deals to scale commercialization.

Strategic reimbursement Tyrvaya's inclusion on Express Scripts National Formularies indicates payer interest; this sets the stage for upstream oncology or dry-eye adjuncts, enabling opportunistic discussions about bundled ocular therapy solutions and value-based pricing with payers and MSOs.

Compliance and governance Recent leadership promotions in compliance and ethics highlight a strong governance posture that can support enterprise sales conversations with risk-averse customers, insurers, and hospital systems seeking robust compliance frameworks in partnerships.

Financial readiness Funding of over a hundred million and revenue in the tens of millions position Oyster Point as a credible partner for co-development, milestone-based collaborations, or joint ventures aimed at expanding ophthalmic therapy pipelines.